Bicycle Therapeutics plc American Depositary Shares (BCYC) Stock Price

BCYCStock

$4.39−39.01%52W

Market Cap$307.27M

P/E—

PEG Ratio—

Div yield—

Beta1.68

BCYC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-30.76%

Price vs S&P 500 (4W)6.85%

VGM Score53.05

Book Value / Share (Quarterly)$7.31

P/TBV (Annual)2.17x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)71.22%

Cash Flow / Share (Quarterly)$-2.98

Price vs S&P 500 (YTD)-50.80%

Net Profit Margin (TTM)-311.11%

EPS (TTM)$-2.74

10-Day Avg Trading Volume0.35M

EPS Excl Extra (TTM)$-2.74

Revenue Growth (5Y)47.52%

EPS (Annual)$-3.16

ROI (Annual)-35.85%

Net Profit Margin (5Y Avg)-560.24%

Cash / Share (Quarterly)$7.31

Revenue Growth QoQ (YoY)-78.46%

ROA (Last FY)-30.51%

Revenue Growth TTM (YoY)217.44%

EBITD / Share (TTM)$-2.95

ROE (5Y Avg)-33.37%

Operating Margin (TTM)-343.60%

Cash Flow / Share (Annual)$-3.63

P/B Ratio0.60x

P/B Ratio (Quarterly)0.58x

Net Income / Employee (Annual)$-760,300

EV / Revenue (TTM)-3.34x

Net Interest Coverage (TTM)-26.39x

ROA (TTM)-27.79%

EPS Incl Extra (Annual)$-3.16

Current Ratio (Annual)11.98x

Quick Ratio (Quarterly)11.70x

3-Month Avg Trading Volume0.41M

52-Week Price Return-39.01%

Revenue / Employee (TTM)$212,500

P/S Ratio (Annual)4.20x

Asset Turnover (Annual)0.10x

52-Week High$9.16

Operating Margin (5Y Avg)-599.41%

EPS Excl Extra (Annual)$-3.16

CapEx CAGR (5Y)14.39%

Tangible BV CAGR (5Y)40.61%

26-Week Price Return-19.52%

Quick Ratio (Annual)11.66x

13-Week Price Return-2.70%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.08x

Enterprise Value$-204.20M

Revenue / Share Growth (5Y)14.06%

Asset Turnover (TTM)0.09x

Book Value / Share Growth (5Y)14.21%

Revenue / Employee (Annual)$252,000

Pretax Margin (Annual)-301.45%

Cash / Share (Annual)$9.05

3-Month Return Std Dev37.03%

Net Income / Employee (TTM)$-661,200

ROE (Last FY)-35.90%

Net Interest Coverage (Annual)-28.94x

EPS Basic Excl Extra (Annual)$-3.16

Receivables Turnover (TTM)378.26x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.74

Receivables Turnover (Annual)26.98x

ROI (TTM)-33.17%

P/S Ratio (TTM)4.98x

Pretax Margin (5Y Avg)-566.76%

Revenue / Share (Annual)$1.05

Tangible BV / Share (Annual)$9.06

Price vs S&P 500 (52W)-57.32%

Year-to-Date Return-38.84%

5-Day Price Return8.52%

EPS Normalized (Annual)$-3.16

ROA (5Y Avg)-23.98%

Net Profit Margin (Annual)-301.66%

Month-to-Date Return12.18%

Cash Flow / Share (TTM)$-4.79

EBITD / Share (Annual)$-3.47

Operating Margin (Annual)-340.38%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-31.47%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.74

P/TBV (Quarterly)1.41x

P/B Ratio (Annual)0.77x

Pretax Margin (TTM)-308.28%

Book Value / Share (Annual)$8.79

Price vs S&P 500 (13W)-5.49%

Beta1.68x

Revenue / Share (TTM)$0.88

ROE (TTM)-33.22%

52-Week Low$3.75

gGradeB

mGradeC

vgmGradeC

BCYC Earnings Surprise History

Q2 25-1.14est. -0.93

Q3 25-0.85est. -1.07

Q4 25-0.29est. -0.95

Q1 26-0.87est. -0.65

Q2 26-0.72est. -0.58

BCYC Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

4.06

4.12

4.06

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
BCYCBicycle Therapeutics plc American Depositary Shares	—	B	C	$4.39
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Bicycle Therapeutics plc American Depositary Shares

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing Bicycles, a novel class of constrained synthetic peptides designed to selectively target cancer cells. Its lead candidate, BT1718, combines a Bicycle targeting moiety with a tumor-killing toxin for oncology indications with high unmet medical needs. The company operates in the United States and United Kingdom.